Dr. Eric M. Weaver, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of New Mexico School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 373
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of New Mexico School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
TN license 44635 -
Critical Care Medicine (Internal Medicine) Physician
TN license 44635
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Parkwest Medical Center Knoxville, TN
- Fort Sanders Regional Medical Center Knoxville, TN
- Methodist Medical Center of Oak Ridge Oak Ridge, TN
- Fort Loudoun Medical Center Lenoir City, TN
- Starr Regional Medical Center Athens Athens, TN
Medical groups
- Statcare Inpatient LLC (109 clinicians)
- Statcare Outpatient LLC (28 clinicians)
- Methodist Medical Center (8 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 373
- Services billed
- 2,929
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 173 | 106 |
| Test to measure expiratory airflow and volume | 124 | 94 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 109 | 47 |
| X-ray of chest, 2 views | 104 | 89 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 96 | 41 |
| Critical care, first 30-74 minutes | 96 | 42 |
| Established patient office or other outpatient visit, 20-29 minutes | 89 | 77 |
| Test to examine how well the lungs exchange gases | 84 | 81 |
| Insertion of needle into vein for collection of blood sample | 83 | 54 |
| Test to determine lung volumes using gas dilution or washout | 68 | 66 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Knoxville, TN | 206 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Knoxville, TN | 201 |
| Prednisone Other prescribers in Knoxville, TN | 100 |
| Pirfenidone | 100 |
| Opsumit (macitentan) | 98 |
| Orenitram Er (treprostinil diolamine) | 56 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Knoxville, TN | 53 |
| Furosemide Other prescribers in Knoxville, TN | 52 |
| Uptravi (selexipag) | 52 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Knoxville, TN | 49 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 19 companies reported 97 payments worth $2,777 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $647 |
|---|---|
| United Therapeutics Corporation | $333 |
| GlaxoSmithKline, LLC. | $230 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $216 |
| Insmed, Inc. | $213 |
| Actelion Pharmaceuticals US, Inc. | $149 |
| Abbott Laboratories | $146 |
| Baxter Healthcare | $140 |
| Food and Beverage | $2,777 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 1 companies. The companies reported $195,623 in research payments for these studies, mostly to the institutions running them.
- Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics Corporation · Recruiting · NCT05943535 - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782 - Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics Corporation · Enrolling by invitation · NCT04905693 - Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
United Therapeutics Corporation · Completed · NCT05776225 - DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
United Therapeutics Corporation · Recruiting · NCT06388421
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.